In games this week we spit it out on the Titanfall Beta, Persona 3 Portable and more P3FES, some EVE talk, Outlast, Mark of the Ninja and more.
News is packed with discussion this week. What is Nintendo up to? Thoughts on Smash Bros. What will get you to buy a Vita? And NPDs to close it out.
© 2005-2006 Irrational Passions Podcast : IP166: TitanFumble Bundle | Design by Andreas Viklund | Powered by Libsyn
All lawsuits are pursued under a contingency fee agreement, which means that there are no out-of-pocket expenses to hire our risperdal attorneys and we receive no fees unless a gynecomastia settlement is received.
Ionis Pharmaceuticals Appoints Damien McDevitt as Chief Business Officer | Ionis Pharmaceuticals, Inc.
CARLSBAD, Calif., June 18, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Damien McDevitt, Ph.D. has joined the company as chief business officer. In his role, Dr. McDevitt will serve as a member of Ionis' executive leadership team and will provide strategic guidance and lead Ionis' corporate development activities, including corporate communications, business development, patient advocacy, competitive intelligence and alliance management.
"Damien is a highly experienced and accomplished leader in the pharmaceutical industry. His strong background in both science and business enable him to contribute broadly in all areas of the company," said Brett P. Monia, chief operating officer and senior vice president, translational medicine. "His leadership will be invaluable as we continue to advance our large pipeline of Ionis-owned and partnered programs, maximize the commercial success of our drugs and optimize our participation in their commercial success. I am excited about the wealth of experience that Damien brings to Ionis, which will be instrumental as we become a multi-product, sustainably profitable company."
"I am joining Ionis at an exciting time. Just this year, Ionis has seen its first commercial drug for a neurological disease, SPINRAZA, reach blockbuster status. Ionis is continuing to build on this momentum with the planned launches of two new drugs this year and readouts from multiple important clinical studies in the near term from its robust pipeline of over 40 first-in-class or best-in-class drugs across multiple therapeutic areas," said Dr. McDevitt. "I look forward to applying my business and operational experience to complement and augment Ionis' goals to not only be the leader in antisense technology, but also a leader in the biotech industry, bringing important medicines to patients."
Dr. McDevitt joins Ionis from ACADIA Pharmaceuticals, where he served as senior vice president, corporate development. Prior to joining ACADIA, Dr. McDevitt was at GSK for more than two decades, where he was instrumental in over 70 global business development transactions involving multiple therapeutic areas, including severe and rare and neuromuscular diseases, among others. He served in various roles with increasing responsibility including vice president, head of business development for R&D Extended Therapy Areas, head of Worldwide Business Development Asia and head of GSK's R&D West Coast Innovation Center. He also worked at GSK Ventures and in anti-infective discovery. Dr. McDevitt is an author of 70 scientific publications and published patents. He attended Trinity College in Dublin, Ireland, where he earned his Ph.D. and undergraduate degree, both in microbiology.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over 45 drugs in development. SPINRAZA® (nusinersen) has been approved in global markets for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. TEGSEDI™ (inotersen) and WAYLIVRA™ (volanesorsen) are two antisense drugs that Ionis discovered and successfully advanced through Phase 3 studies. TEGSEDI is under regulatory review for marketing approval in the U.S., EU and Canada for the treatment of patients with hereditary ATTR, or hATTR, amyloidosis. WAYLIVRA is under regulatory review for marketing approval in the U.S., EU and Canada for the treatment of patients with familial chylomicronemia syndrome, or FCS. WAYLIVRA is also in a Phase 3 study in patients with familial partial lipodystrophy, or FPL. Akcea, an affiliate of Ionis focused on developing and commercializing drugs to treat patients with serious and rare diseases, will commercialize TEGSEDI and WAYLIVRA, if approved. Ionis' patents provide strong and extensive protection for its drugs and technology. Additional information about Ionis is available at www.ionispharma.com.
This press release includes forward-looking statements regarding the therapeutic and commercial potential of SPINRAZA, TEGSEDI (inotersen), WAYLIVRA (volanesorsen) and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis' majority owned subsidiary. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2017, and most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of these and other documents are available from the Company.
Biocorrosion – Influence of bacteria and surface biofilms on the corrosion of steel in presence of argillite
According to the French concept for deep geological disposal, high level radioactive waste will be emplaced in carbon-steel overpacks in a host rock consisting in a Callovo-Oxfordian clayey formation located in the Eastern Paris Basin. These overpacks have to ensure containment for several hundred years. During the first years after closure, they will be in unsaturated and aerated conditions and after a transition period aerated/deaerated the system would be in anaerobiosis. The study presented here is a part of a collaboration between LAPA and the French Institute of Radioprotection and Nuclear Safety (IRSN) in Fontenay-aux-Roses in France. IRSN has been conducting researches in its Tournemire Underground Research Laboratory (URL), a railway tunnel which crosses a Toarcian argillaceous formation. This geological layer is particularly interesting for its physical and chemical properties close to those of the Callovo-Oxfordian formation.
An original corrosion set-up was carried out: steel coupons were placed in drilled argillite with flowing of Tournemire pore water either in absence or in presence of a bacterial strains mix, at various temperatures, in oxic or anoxic conditions, and during one, four or nine months. The aerated conditions were chosen to understand what could take place at the beginning of the storage of the nuclear waste before the anoxic phasis. The mix of bacterial strains is representative of those reported in studies of the deep clayey biodiversity: Sulphate-Reducing Bacteria (SRB), Sulfur-Oxidizing Bacteria (SOB), Iron-Reducing Bacteria (IRB), biofilm forming strains. After the corrosion experiment, the steel coupons (surface and polished transverse sections) were characterized by complementary techniques: µRaman spectroscopy and XRD, so as to identify the crystalline structure of the corrosion products and FESEM at low voltage (5 kV) to evidence bacteria and biofilms and their association to the corrosion products. The bacterial diversity on the surface of steel coupons was also characterized by DNA Preparation and sequencing at IPREM (Equipe Environnement et Microbiologie). The corrosion rate was also determined for all the coupons.
The aim of this study is to determine the bacterial impacts on steel corrosion in conditions prevailing in a repository in the presence of a complex biodiversity with the following questions:
Let us see an illustration concerning the system corroded in aerobiosis at 25°C. Without added bacteria, FeIII-oxyhydroxides as lepidocrocite (